Adverse effects of azacitidine: Onset, duration, and treatment

Advances in Therapy

Volumn 28, Issue SUPPL. 4, 2011, Pages 1-5

  Martínez Francés, Antonio ^a  

^a Hospital Universitario Santa Maria del Rosell   (Spain)

Author keywords

adverse effects; azacitidine; myelodysplastic syndromes

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; AZACITIDINE; CYTARABINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PRIMROSE OIL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ALLOPATHY; ANEMIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CONSTIPATION; CYTOPENIA; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PRACTICE GUIDELINE; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VOMITING;

AGE OF ONSET; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DISEASE MANAGEMENT; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; FATIGUE; GASTROINTESTINAL DISEASES; HUMANS; MAXIMUM TOLERATED DOSE; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; PROGNOSIS; SURVIVAL RATE;

EID: 79959625105     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0021-5     Document Type: Review

References (14)

1. Valent P, Horny HP, Bennet JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:72-36.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2098.
3. Anderson JE, Appelbaunm FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndromes. Blood. 1993;82:677-683.
4. Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836-846. (Pubitemid 44154615)
5. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440. (Pubitemid 34525728)
6. Fenaux P, Mufti GJ, Hellstrom-Linndberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodisplastic syndromes: a randomized, open-label, phase III study. Lancet Oncol. 2009;10:223-232.
7. Silverman LR, Fenaux P, Mufti GJ, et al. The effects of continued azacitidine (AZA) treatment cycles on response in higher-risk patients with myelodysplastic syndromes. Blood. 2008;112:227. Abstract 227.
8. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodisplastic syndromes. J Clin Oncol. 2009;27:1850-1856
9. Ross SD, Allen E, Probst CA, et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist. 2007;12:1264-1273. (Pubitemid 350106357)
10. MoyoV, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodisplastic syndromes: a meta-analysis. Ann Hematol. 2008;87:527-536.
11. Fenaux P, Bowen D, Gattermann N, et al. Practical use of azacitidine in higher-risk myelodisplastic syndromes: an expert panel opinion. Leuk Res. 2010;34:1410-1416.
12. Vidaza® (azacitidine injection) [product information]. Celgene Europe Ltd. Boudry, Switzerland; 2008.
13. Bassy GN, Kantarjian H, Issa JP, et al. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk. 2010;10:205-210.
14. Platzbecker U, Aul C, Ehninger G, et al. Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil. Ann Hematol. 2010;89:427-428.